Targeting oncogenic BRAF and aberrant MAPK activation in the treatment of cutaneous melanoma

This publication has 165 references indexed in Scilit:

• Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion
  Nature, 2012
• A Landscape of Driver Mutations in Melanoma
  Cell, 2012
• KIT as a Therapeutic Target in Metastatic Melanoma
  JAMA, 2011
• Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K
  Cancer Cell, 2010
• Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
  Cell, 2010
• ERK-dependent threonine phosphorylation of EGF receptor modulates receptor downregulation and signaling
  Cellular Signalling, 2008
• CRAF Autophosphorylation of Serine 621 Is Required to Prevent Its Proteasome-Mediated Degradation
  Molecular Cell, 2008
• Human cutaneous melanoma; a review of NRAS and BRAF mutation frequencies in relation to histogenetic subclass and body site
  Molecular Oncology, 2007
• Regulation of MAPKs by growth factors and receptor tyrosine kinases
  Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2007
• Mutations of the BRAF gene in human cancer
  Nature, 2002